Evaluating the results of the Momguard noninvasive prenatal test
Hae‐Jin Hu, Young-Jun Kwon, Mi‐Jin Oh, Jihun Kim, Dae-Yeon Cho, Dong-Hee Seo
Abstract
Open-access reader
Hae‐Jin Hu, Young-Jun Kwon, Mi‐Jin Oh, Jihun Kim, Dae-Yeon Cho, Dong-Hee Seo
Abstract
Open-access reader
JGM from an NT ultrasound and maternal serum tests has been used for noninvasive prenatal test (NIPT) [4].If a test result indicates a sample is 'screen positive', chorionic villus sampling (CVS) or amniocentesis is performed to confirm the result.However, current maternal serum screening tests have a relatively low detection rate (50-95%) and high false-positive rate (5%) [5].CVS and amniocentesis carry the risk of fetal loss, since they are invasive procedures and may present additional emotional burdens for the mother.The discovery of the existence of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 by Lo et al. [6] led to a new era for NIPT.Within the last two decades, advanced technologies such as digital polymerase chain reaction or massively parallel Evaluating the results of the Momguard noninvasive prenatal test
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
JGM from an NT ultrasound and maternal serum tests has been used for noninvasive prenatal test (NIPT) [4].If a test result indicates a sample is 'screen positive', chorionic villus sampling (CVS) or amniocentesis is performed to confirm the result.However, current maternal serum screening tests have a relatively low detection rate (50-95%) and high false-positive rate (5%) [5].CVS and amniocentesis carry the risk of fetal loss, since they are invasive procedures and may present additional emotional burdens for the mother.The discovery of the existence of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 by Lo et al. [6] led to a new era for NIPT.Within the last two decades, advanced technologies such as digital polymerase chain reaction or massively parallel Evaluating the results of the Momguard noninvasive prenatal test
Key concepts: Prenatal diagnosis, Test (biology), Prenatal screening, Medicine, Obstetrics, Pregnancy, Genetics, Biology